The INK4A/ARF locus: Role in cell cycle control and apoptosis and implications for glioma growth

Journal of Neuro-Oncology

Volumn 51, Issue 3, 2001, Pages 219-229

  Ivanchuk, Stacey M ^a   Mondal, Soma ^a   Dirks, Peter B ^a,b   Rutka, James T ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Apoptosis; Growth arrest; INK4A ARF; p53; pRB; Tumour suppressor

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P16; PROTEIN P19; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR;

APOPTOSIS; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELLULAR PARAMETERS; CHROMOSOME 9P; EXPERIMENTAL MODEL; GENE DELETION; GENE LOCUS; GENE MUTATION; GENETIC CODE; GLIOMA CELL; HUMAN; KNOCKOUT MOUSE; MALIGNANT TRANSFORMATION; MITOSIS INHIBITION; NONHUMAN; REVIEW; SENESCENCE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CELL CYCLE; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GLIOMA; HUMANS; PROTEINS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 0035013213     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010632309113     Document Type: Review

References (70)

1. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-30, 1995
2. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-31, 1997
3. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, 3rd, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-40, 1994
4. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-7, 1993
5. Duro D, Bernard O, Della Valle V, Berger R, Larsen CJ: A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 11: 21-9, 1995
6. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D: A novel p16INK4A transcript. Cancer Res 55: 2995-7, 1995
7. Quelle DE, Ashmun RA, Hannon GJ, Rehberger PA, Trono D, Richter KH, Walker C, Beach D, Sherr CJ, Serrano M: Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene 11: 635-45, 1995
8. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A: Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55: 2988-94, 1995
9. Zindy F, van Deursen J, Grosveld G, Sherr CJ, Roussel MF: INK4d-deficient mice are fertile despite testicular atrophy. Mol Cell Biol 20: 372-8, 2000
10. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L, Xiong Y: CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12: 2899-911, 1998
11. Roussel MF: The INK4 family of cell cycle inhibitors in cancer. Oncogene 18: 5311-7, 1999
12. Pavletich NP: Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 287: 821-8, 1999
13. Koh J, Enders GH, Dynlacht BD, Harlow E: Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375: 506-10, 1995
14. Noh SJ, Li Y, Xiong Y, Guan KL: Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6. Cancer Res 59: 558-64, 1999
15. McConnell BB, Gregory FJ, Stott FJ, Hara E, Peters G: Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol Cell Biol 19: 1981-9, 1999
16. Parry D, Bates S, Mann DJ, Peters G: Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. Embo J 14: 503-11, 1995
17. Parry D, Mahony D, Wills K, Lees E: Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol Cell Biol 19: 1775-83, 1999
18. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP: Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395: 237-43, 1998
19. Brotherton DH, Dhanara V, Wick S, Brizuela L, Domaille PJ, Volyanik E, Xu X, Parisini E, Smith BO, Archer SJ: Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d. Nature 395: 244-50, 1998
20. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J: Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375: 503-6, 1995
21. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN: CDKN2/p16 or RB alterations occur in the ma ority of glioblastomas and are inversely correlated. Cancer Res 56: 150-3, 1996
22. Li Y, Nichols MA, Shay JW, Xiong Y: Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 54: 6078-82, 1994
23. Shapiro GI, Edwards CD, Ewen ME, Rollins BJ: p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol 18: 378-87, 1998
24. Liggett WH Jr, Sewell DA, Rocco J, Ahrendt SA, Koch W, Sidransky D: p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res 56: 4119-23, 1996
25. Arap W, Knudsen E, Sewell DA, Sidransky D, Wang JY, Huang HJ, Cavenee WK: Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway. Oncogene 15: 2013-20, 1997
26. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D: Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1: 20-6, 1999
27. Tao W, Levine AJ: P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 96: 6937-41, 1999
28. Robertson KD, Jones PA: The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 18: 6457-73, 1998
29. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH: The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. Embo J 17: 5001-14, 1998
30. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000, 1995
31. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ: Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95: 8292-7, 1998
32. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF: Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-33, 1998
33. de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW: E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 12: 2434-42, 1998
34. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-37, 1996
35. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G: Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 16: 859-67, 1996
36. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC: Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 93: 13742-7, 1996
37. Zindy F, Quelle DE, Roussel MF, Sherr CJ: Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15: 203-11, 1997
38. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-59, 1997
39. Uhrbom L, Nister M, Westermark B: Induction of senescence in human malignant glioma cells by p16INK4A. Oncogene 15: 505-14, 1997
40. Stein GH, Drullinger LF, Soulard A, Dulic V: Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol 19: 2109-17, 1999
41. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW: Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602, 1997
42. Kamijo T, van de Kamp E, Chong MJ, Zindy F, Diehl JA, Sherr CJ, McKinnon PJ: Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. Cancer Res 59: 2464-9, 1999
43. Carnero A, Hudson JD, Price CM, Beach DH: p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol 2: 148-55, 2000
44. Schreiber M, Muller WJ, Singh G, Graham FL: Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene 18: 1663-76, 1999
45. Kim M, Katayose Y, Rojanala L, Shah S, Sgagias M, Jang L, Jung YJ, Lee SH, Hwang SG, Cowan KH: Induction of apoptosis in p16INK4A mutant cell lines by adenovirus-mediated overexpression of p16INK4A protein. Cell Death Differ 7: 706-711, 2000
46. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL: Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13: 2658-69, 1999
47. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW: INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13: 2670-7, 1999
48. Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Berkvig R, Yung WK, Sawaya R, Kyritsis AP, Rao JS: Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 15: 2049-57, 1997
49. Fahraeus R, Lane DP: The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. Embo J 18: 2106-18, 1999
50. Marshall JF and Hart IR: The role of alpha v-integrins in tumour progression and metastasis. Semin Cancer Biol 7: 129-38, 1996
51. van Lookeren Campagne M, Gill R: Tumor-suppressor p53 is expressed in proliferating and newly formed neurons of the embryonic and postnatal rat brain: comparison with expression of the cell cycle regulators p21Waf1/Cip1, p27Kip1, p57Kip2, p16Ink4a, cyclin G1, and theproto-oncogene Bax. J Comp Neurol 397: 181-98, 1998
52. Watanabe G, Pena P, Shambaugh GE 3rd, Haines GK 3rd, Pestell RG: Regulation of cyclin dependent kinase inhibitor proteins during neonatal cerebella development. Brain Res Dev Brain Res 108: 77-87, 1998
53. Nielsen GP, Stemmer-Rachamimov AO, Shaw J, Roy JE, Koh J, Louis DN: Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest 79: 1137-43, 1999
54. Quelle DE, Cheng M, Ashmun RA, Sherr CJ: Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc Natl Acad Sci USA 94: 669-73, 1997
55. Holland EC, Hively WP, DePinho RA, Varmus HE: A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12: 3675-85, 1998
56. Ruas M, Peters G: The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378: F115-77, 1998
57. Byeon IJ, Li J, Ericson K, Selby TL, Tevelev A, Kim HJ, O'Maille P, Tsai MD: Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase. Mol Cell 1: 421-31, 1998
58. Fitz Gerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ: Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 93: 8541-5, 1996
59. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-92, 1995
60. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG: Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60: 129-33, 2000
61. Melendez B, Malumbres M, de Castro IP, Santos J, Pellicer A, Fernandez-Piqueras J: Characterization of the murine p19(ARF) promoter CpG island and its methylation pattern in primary lymphomas. Carcinogenesis 21: 817-21, 2000
62. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353-8, 1994
63. Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the ma ority of glioblastomas. Cancer Res 54: 6321-4, 1994
64. He J, Olson JJ, James CD: Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 55: 4833-6, 1995
65. Ichimura K, Schmidt EE, Goike HM, Collins VP: Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13: 1065-72, 1996
66. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP: Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60: 417-24, 2000
67. Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A, Van Meir EG: p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19: 3816-22, 2000
68. Dirks PB, Patel K, Hubbard SL, Ackerley C, Hamel PA, Rutka JT: Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells. Oncogene 15: 2037-48, 1997
69. Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA, Kyritsis AP: Adenovirus- mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12: 103-10, 1996
70. Costanzi-Strauss E, Strauss BE, Naviaux RK, Haas M: Restoration of growth arrest by p16INK4, p21WAF1, pRB, and p53 is dependent on the integrity of the endogenous cell-cycle control pathways in human glioblastoma cell lines. Exp Cell Res 238: 51-62, 1998